Method to detect prostate cancer in a sample
First Claim
Patent Images
1. A composition comprising:
- (a) a urine sample from a subject having or suspected of having prostate cancer, said urine sample comprising at least one prostate cell or nucleic acid extract thereof;
(b) a first oligonucleotide or first primer pair for performing an RNA hybridization and/or amplification reaction on mRNA contained in said urine sample, said first oligonucleotide or first primer pair being specific for a prostate cancer associated PCA3 mRNA molecule which is;
(i) a polynucleotide molecule comprising the sequence of SEQ ID NO;
9, 10 or 13;
(ii) a polynucleotide molecule that hybridizes under high stringency conditions to (i), wherein said high stringency conditions comprise a hybridization at 65°
C. in 6×
SSC or 5×
SSPE, 5×
Denhardt'"'"'s solution, 0.5% SDS and 100 μ
g/ml denatured carrier DNA and a washing at 65°
C. in 0.2×
SSC/0.1% SDS;
or(iii) a polynucleotide molecule fully complementary to (i) or (ii); and
(c) a second oligonucleotide or second primer pair for performing a second RNA hybridization and/or amplification reaction on mRNA contained in said urine sample, said second oligonucleotide or second primer pair being specific for a prostate-specific mRNA molecule,wherein at least one oligonucleotide in the composition is a labeled oligonucleotide, and the at least one labeled oligonucleotide includes at least one of (i) the first oligonucleotide, (ii) a primer of the first primer pair, (iii) the second oligonucleotide, or (iv) a primer of the second primer pair.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides methods to detect prostate cancer by detecting the RNA encoded by PCA3. The disclosure provides a method for determining a predisposition, or presence of prostate cancer comprising: (a) contacting a sample with at least one oligonucleotide that hybridizes to a PCA3 polynucleotide; (b) detecting an amount of PCA3 and second prostate-specific polynucleotides; and (c) comparing the amount of PCA3 polynucleotide that hybridizes to the oligonucleotide to a predetermined cut off value, and determining the presence or absence of prostate cancer. Diagnostic kits are provided for detecting prostate cancer or the risk of developing same comprising: (a) at least one container means containing at least one oligonucleotide probe or primer that hybridizes to PCA3 (b) at least one oligonucleotide probe or primer that hybridizes with a second prostate specific nucleic acid; and (c) reagents for detecting PCA3 and the second prostate specific nucleic acid.
72 Citations
20 Claims
-
1. A composition comprising:
-
(a) a urine sample from a subject having or suspected of having prostate cancer, said urine sample comprising at least one prostate cell or nucleic acid extract thereof; (b) a first oligonucleotide or first primer pair for performing an RNA hybridization and/or amplification reaction on mRNA contained in said urine sample, said first oligonucleotide or first primer pair being specific for a prostate cancer associated PCA3 mRNA molecule which is; (i) a polynucleotide molecule comprising the sequence of SEQ ID NO;
9, 10 or 13;(ii) a polynucleotide molecule that hybridizes under high stringency conditions to (i), wherein said high stringency conditions comprise a hybridization at 65°
C. in 6×
SSC or 5×
SSPE, 5×
Denhardt'"'"'s solution, 0.5% SDS and 100 μ
g/ml denatured carrier DNA and a washing at 65°
C. in 0.2×
SSC/0.1% SDS;
or(iii) a polynucleotide molecule fully complementary to (i) or (ii); and (c) a second oligonucleotide or second primer pair for performing a second RNA hybridization and/or amplification reaction on mRNA contained in said urine sample, said second oligonucleotide or second primer pair being specific for a prostate-specific mRNA molecule, wherein at least one oligonucleotide in the composition is a labeled oligonucleotide, and the at least one labeled oligonucleotide includes at least one of (i) the first oligonucleotide, (ii) a primer of the first primer pair, (iii) the second oligonucleotide, or (iv) a primer of the second primer pair. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
-
-
19. A composition comprising:
-
(a) a urine sample from a subject having or suspected of having prostate cancer, said urine sample comprising at least one prostate cell or nucleic acid extract thereof; (b) a first primer pair including a first promoter-primer for performing an RNA amplification reaction on mRNA contained in said urine sample, the first promoter-primer being specific for a prostate cancer associated PCA3 mRNA molecule which is; (i) a polynucleotide molecule comprising the sequence of SEQ ID NO;
9, 10 or 13;(ii) a polynucleotide molecule that hybridizes under high stringency conditions to (i), wherein said high stringency conditions comprise a hybridization at 65°
C. in 6×
SSC or 5×
SSPE, 5×
Denhardt'"'"'s solution, 0.5% SDS and 100 μ
g/ml denatured carrier DNA and a washing at 65°
C. in 0.2 SSC/0.1% SDS;
or(iii) a polynucleotide molecule fully complementary to (i) or (ii); and (c) a second primer pair including a second promoter-primer for performing a second RNA amplification reaction on mRNA contained in said urine sample, said second oligonucleotide or second primer pair being specific for a prostate-specific mRNA molecule. - View Dependent Claims (20)
-
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeGen-Probe Incorporated (Hologic Incorporated)
-
Original AssigneeGen-Probe Incorporated (Hologic Incorporated)
-
InventorsFradet, Yves, Chypre, Camille, Piche, Lyson, Garon, Genevieve
-
Primary Examiner(s)Aeder, Sean E
-
Application NumberUS15/093,214Publication NumberTime in Patent Office810 DaysField of SearchNoneUS Class CurrentCPC Class CodesC12Q 1/6886 for cancer immunoassay for ...C12Q 2600/158 Expression markersC12Q 2600/16 Primer sets for multiplex a...
